Latest Conference Articles

February 20th 2016, 10:50am

Multidisciplinary Head and Neck Cancer Symposium

Jose P. Zevallos, MD, MPH, FACS, assistant professor, director of Oncologic Research, University of North Carolina School of Medicine, discusses a study that examined the molecular profile of patients with HPV-positive oropharyngeal squamous cell carcinoma (SCC) stratified by smoking status.

February 20th 2016, 9:00am

Multidisciplinary Head and Neck Cancer Symposium

The use of induction chemotherapy for advanced head and neck squamous cell carcinoma does not improve overall survival.

February 19th 2016, 4:44pm

Multidisciplinary Head and Neck Cancer Symposium

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses nivolumab's potential as a treatment of patients with head and neck cancer, as reported in the CheckMate-141 study.

February 19th 2016, 3:18pm

Multidisciplinary Head and Neck Cancer Symposium

Patients with locally advanced head and neck cancer should be screened for social isolation and financial hardship, as these factors play a role in their ability to stay on medication, minimize hospital stays, and achieve optimal health outcomes.

February 19th 2016, 3:08pm

Multidisciplinary Head and Neck Cancer Symposium

Keith C. Bible, MD, PhD, medical oncologist, Mayo Clinic, discusses the impact that lenvatinib (Lenvima) has had on the treatment landscape of differentiated thyroid cancer.

February 19th 2016, 8:51am

Multidisciplinary Head and Neck Cancer Symposium

In patients treated with definitive radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma, most recurrences can be detected via imaging at 3 months and physical examinations during the first 6 months after treatment.

February 19th 2016, 7:55am

Multidisciplinary Head and Neck Cancer Symposium

Tanguy Y. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the impact of immunotherapy agents as treatment of patients with head and neck cancer.

February 19th 2016, 6:03am

Multidisciplinary Head and Neck Cancer Symposium

Concurrent chemoradiation significantly improved overall survival compared with radiation therapy alone for elderly patients with locally advanced head and neck cancers.

February 18th 2016, 3:40pm

Multidisciplinary Head and Neck Cancer Symposium

Ezra Cohen, MD, associate director, Moores Cancer Center, professor of Medicine, University of California, San Diego Health System, discusses tumor biomarker association with clinical outcomes in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with afatinib versus methotrexate.

February 18th 2016, 2:57pm

Multidisciplinary Head and Neck Cancer Symposium

Tobacco-associated mutations accumulate over time in smokers with HPV-positive oropharyngeal squamous cell cancer, resulting in less dependence on E6/E7 and other HPV-associated mutations.

January 26th 2016, 12:43pm

Gastrointestinal Cancers Symposium (ASCO GI)

Mismatch repair-deficient gastrointestinal tumors are highly responsive to checkpoint blockade with anti-PD-1 therapy.

January 26th 2016, 9:13am

Gastrointestinal Cancers Symposium (ASCO GI)

A potential biomarker to guide chemotherapy for metastatic colorectal cancer failed to stratify patients by progression-free survival or responsiveness to bevacizumab.

January 26th 2016, 7:56am

Gastrointestinal Cancers Symposium (ASCO GI)

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses tumor response in the CLARINET study, which examined lanreotide depot versus placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

January 26th 2016, 7:08am

Gastrointestinal Cancers Symposium (ASCO GI)

Marcovalerio Melis, MD, associate professor, Department of Surgery, NYU Langone Medical Center, discusses a study examining if surgery can be avoided in patients with advanced rectal cancer by using diffusion-weighted magnetic resonance imaging to predict pathologic response.

January 25th 2016, 3:09pm

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with metastatic colorectal cancer (mCRC) had marginal yet inconsistent improvement in clinical outcomes when treated with a three-drug chemotherapy regimen plus bevacizumab compared with a doublet-bevacizumab regimen.

January 25th 2016, 11:31am

Gastrointestinal Cancers Symposium (ASCO GI)

Neoadjuvant treatment with carboplatin and paclitaxel-based chemotherapy produced a 27.9% pathologic complete response rate in patients with resectable esophageal cancer, according to results of the NEOSCOPE trial.

January 23rd 2016, 5:02pm

Gastrointestinal Cancers Symposium (ASCO GI)

The investigational anti–PD-L1 antibody avelumab demonstrated clinical activity as a second-line and maintenance therapy for patients with unresectable gastric or gastroesophageal junction cancer.

January 23rd 2016, 3:15pm

Gastrointestinal Cancers Symposium (ASCO GI)

Safi Shahda, MD, assistant professor of Clinical Medicine, Indiana University School of Medicine, discusses a phase Ib study examining the cancer stem cell pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.

January 23rd 2016, 2:40pm

Gastrointestinal Cancers Symposium (ASCO GI)

Theodore S. Hong, MD, director, Gastrointestinal Service, Department of Radiation Oncology, discusses high-dose hypofractionated proton beam therapy for unresectable primary liver cancers.

January 23rd 2016, 1:27pm

Gastrointestinal Cancers Symposium (ASCO GI)

Nearly a quarter of patients with resectable hepatocellular carcinoma experienced major tumor necrosis of greater than or equal to 50% following preoperative treatment with sorafenib.